Stallion India Fluorochemicals Ltd
Stallion India Fluorochemicals Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 earnings call: what management said on revenue, margins and capex.
Guidance rank: #9 of 71 in Chemicals & Petrochemicals
See the sector's top 10 — free with your mobile number.
The short version
Stallion India Fluorochemicals targets a significant growth trajectory aiming to reach INR 2,500 crore in turnover by 2030, implying several times growth from current levels. Stallion India Fluorochemicals targets a significant growth trajectory with a five-year vision to reach INR 2,500 crore in turnover by 2030.
From Stallion India Fluorochemicals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Stallion India Fluorochemicals targets a significant growth trajectory aiming to reach INR 2,500 crore in turnover by 2030, implying several times growth from current levels.
- Growth will be driven by a series of manufacturing plants, starting with a 5,000-ton plant expected to add around INR 135 crore turnover in the first year and INR 270 crore in the next.
- Expansion plans include additional plants beyond the initial one, each larger and expected to generate higher revenues, contributing to multi-fold growth rather than just 30-35% CAGR.
- Incremental revenues from the upcoming Mambattu, Khalapur, and Rajasthan plants are expected to notably increase from 2026 onwards.
2 more points from Stallion India Fluorochemicals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Stallion India Fluorochemicals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- CapEx of approximately INR 200 crore planned for manufacturing R-32 refrigerant plant.
- New manufacturing plants planned in a series, with the first plant serving as a learning experience; subsequent plants to be larger in scale.
- Khalapur and Mambattu facilities expected to be operational by November 2025, contributing incrementally to revenue starting FY26.
- Rajasthan manufacturing facility expected to start production by mid-2026.
- Planned capacity expansions to significantly enhance turnover, aiming to add INR 135 crore in the first year and INR 270 crore in the second year from the initial manufacturing plant.
2 more points from Stallion India Fluorochemicals Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Stallion India Fluorochemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company currently has an order book, but immediate impact may not be visible in revenues.
- Real impact from new plants and orders expected from April onwards.
- HFO business is currently limited in India; demand is mostly from new projects and export-driven growth.
2 more points from Stallion India Fluorochemicals Ltd's call on order book
Create a free account to keep reading this call
Stallion India Fluorochemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹110 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Stallion India Fluorochemicals Ltd's management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Balaji Amines (Q1 FY26)
Q1FY26 consolidated revenue from operations: ₹367 crore, up 2% quarter-on-quarter from ₹361 crore in Q4FY25, but down 7% year-on-year from ₹393 crore in Q1FY25…
- Linde India Ltd (Q1 FY26)
Net Revenue for FY ended Mar’25 was INR 24,854 million, down 10.2% (–2,833 million) YoY from INR 27,687 million. Key concall takeaways from Linde India Ltd's…
- Vidhi Specialty Food Ingredients Ltd (Q1 FY26)
87.9 Crores . Key concall takeaways from Vidhi Specialty Food Ingredients Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- Chemcon Speciality Chemicals Ltd (Q1 FY26)
Q1 FY26 revenue from operations: ₹53.5 Cr, up 18% YoY from ₹45.5 Cr in Q1 FY25 (Page 7 & 6). Key concall takeaways from Chemcon Speciality Chemicals Ltd's Q1…
Potential multibaggers · Q2 FY27
Potential multibaggers in Chemicals & Petrochemicals
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Stallion India Fluorochemicals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Stallion India Fluorochemicals Ltd Q1 FY26 results?
Stallion India Fluorochemicals targets a significant growth trajectory aiming to reach INR 2,500 crore in turnover by 2030, implying several times growth from current levels. Stallion India Fluorochemicals targets a significant growth trajectory with a five-year vision to reach INR 2,500 crore in turnover by 2030.
What is Stallion India Fluorochemicals Ltd share price analysis?
Stallion India Fluorochemicals Ltd currently shows a neutral. The stock trades at a P/E of 51.3 with a market cap of ₹2,668 Cr. Investors should review the full earnings analysis for detailed insights.
Is Stallion India Fluorochemicals Ltd planning capital expenditure?
CapEx of approximately INR 200 crore planned for manufacturing R-32 refrigerant plant.
Keep Stallion India Fluorochemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.